Clinical Trials Directory

Trials / Completed

CompletedNCT03362437

Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants

A Study to Evaluate the Pharmacokinetics of BMS-986177 From Form A and Form B in Healthy Participants

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

Assess the pharmacokinetics (fasting and fed), safety, and tolerability of BMS-986177 following oral dosing of Form A and Form B

Conditions

Interventions

TypeNameDescription
DRUGBMS-986177Form A
DRUGBMS-986177Form B

Timeline

Start date
2017-11-15
Primary completion
2017-12-28
Completion
2017-12-28
First posted
2017-12-05
Last updated
2018-03-14

Locations

1 site across 1 country: United Kingdom

Regulatory

Source: ClinicalTrials.gov record NCT03362437. Inclusion in this directory is not an endorsement.

Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants (NCT03362437) · Clinical Trials Directory